Publications by authors named "Fabienne Di Giambattista"
CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen.
Transpl Int
February 2016
An increased basiliximab dose may saturate T-cell CD25 receptors in kidney transplant patients receiving calcineurin inhibitor (CNI)-free immunosuppression. In a 12-week study, 16 de novo kidney transplant patients were randomized to (i) 40 mg basiliximab with cyclosporine [n = 3] (controls), (ii) 80 mg basiliximab with cyclosporine [n = 6], or (iii) 80 mg basiliximab with everolimus (CNI-free) [n = 7], all with mycophenolic acid and steroids. Recruitment was stopped prematurely due to increased biopsy-proven acute rejection (BPAR) in the basiliximab 80 mg CNI-free group.
View Article and Find Full Text PDFBackground And Aims: Recurrent hepatitis C after liver transplantation (LT) is associated with rapid fibrosis progression. The aim of this study was to evaluate the cumulative risk for severe fibrosis and the factors influencing it.
Patients And Methods: Two hundred and fifty LT patients were included 1 to 15years after LT.
Conversion from everolimus with low-exposure cyclosporine to everolimus with mycophenolate sodium maintenance therapy in kidney transplant recipients: a randomized, open-label multicenter study.
Ann Transplant
August 2012
Article Synopsis
- This study investigates the impact of switching from a low-exposure calcineurin inhibitor (CNI) to mycophenolate sodium in kidney transplant patients taking everolimus and corticosteroids after one year of surgery.
- Results showed a small improvement in kidney function (measured by mGFR) for the CNI-free group compared to those who continued with CNI, although the difference wasn't statistically significant.
- The findings suggest that eliminating CNI might maintain efficacy and could be beneficial, but the small sample size means larger studies are needed to confirm these results.
A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients.
Clin Nephrol
February 2012
Mycophenolic acid (MPA) dose is frequently reduced in tacrolimus-treated kidney transplant patients, but alternatively the recommended MPA dose can be maintained with reduced tacrolimus exposure. In a 6-month, multicenter, randomized, openlabel study, maintenance kidney transplant patients receiving MPA (mycophenolate mofetil 1g/d or enteric-coated mycophenolate sodium (EC-MPS) 720 mg/d) and tacrolimus were randomized to convert to EC-MPS 1,440 mg/d with reduced tacrolimus (n = 46), or receive EC-MPS 720 mg/d with unchanged tacrolimus (n = 48). Mean estimated GFR (eGFR, aMDRD) at Month 6 was 49.
View Article and Find Full Text PDFEfficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.
Transpl Int
November 2010
Article Synopsis
- Immediate use of everolimus (mTOR inhibitor) post-kidney transplant can limit the need for calcineurin inhibitors while posing risks of delayed graft function (DGF) and impaired wound healing.
- The CALLISTO study involved 139 deceased-donor kidney transplant patients split into immediate (IE) and delayed (DE) everolimus groups, showing similar outcomes in primary endpoints after 12 months.
- Both groups had comparable rates of acute rejection and renal function, indicating no significant benefit in delaying everolimus initiation for patients at risk of DGF.
Article Synopsis
- There are concerns that starting sirolimus too soon after kidney transplantation may lead to delayed graft function (DGF) and wound healing issues, prompting the idea to delay everolimus administration instead.
- A study was conducted to assess the effects of starting everolimus immediately after transplantation versus delaying it for five weeks in patients at risk for DGF.
- The results showed no significant differences in kidney function recovery, wound healing, or overall treatment tolerance between the immediate and delayed everolimus groups at the 3-month mark.
Background: New-onset diabetes mellitus (NODM)-a common complication of kidney transplantation-is associated with increases in graft loss, morbidity and mortality.
Methods: This is a purely observational study of 527 patients taking a calcineurin inhibitor (CNI), based on data collected at a single routine visit 6-24 months after kidney transplantation. Diabetes was defined according to ADA/WHO guidelines.